Article Text

Download PDFPDF

Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
  1. Sara Monti1,
  2. Silvia Balduzzi2,
  3. Paolo Delvino3,
  4. Elisa Bellis3,
  5. Verdiana Serena Quadrelli3,
  6. Carlomaurizio Montecucco3
  1. 1 Rheumatology Department, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
  2. 2 Rheumatology Department, IRCCS Policlinico San Matteo, Pavia, Italy
  3. 3 Rheumatology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
  1. Correspondence to Dr Sara Monti, Rheumatology, IRCCS Fondazione Policlinico S Matteo, Pavia 27100, Italy; sara.saramonti{at}gmail.com

Statistics from Altmetric.com

Different viral agents are associated with an increased risk of more severe disease course and respiratory complications in immunocompromised patients.1–3 The recent outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) responsible for a severe acute respiratory syndrome (SARS) represents a source of concern for the management of patients with inflammatory rheumatic diseases. Lombardy is the region in Northern Italy with the highest incidence of COVID-19 cases, with more than 33 000 confirmed patients and 1250 requiring admission to the intensive care unit within 1 month. Since the first reports of COVID-19 cases in Italy, we have circulated a survey with a 2-week follow-up contact to patients with chronic arthritis treated with biological disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) followed up at our biological outpatient clinic in Pavia, Lombardy. The survey investigated the patients’ health conditions, the presence of contacts with subjects known to be affected by COVID-19 and management of …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.